Eversept Partners’s Immunocore IMCR Stock Holding History

Eversept Partners’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-39,238	Closed	-$1.18M	–	134
2026 Q1	$1.18M	Buy	+39,238	New	+$1.27M	0.06%	102

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Eversept Partners's IMCR Position: Q2 2026 in Review

Eversept Partners sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 39,238 shares — an estimated $1.18M sold.

Eversept Partners first reported a position in IMCR in Q1 2026 and held it in 1 quarter. The position peaked at $1.18M in Q1 2026. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

Eversept Partners reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
Eversept Partners sold 39,238 Immunocore shares in Q2 2026, an estimated $1.18M.
Eversept Partners first reported a position in Immunocore in Q1 2026 and held it in 1 quarter.
Eversept Partners's Immunocore position peaked at $1.18M in Q1 2026.
136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.